Skip to main content
. Author manuscript; available in PMC: 2019 May 28.
Published in final edited form as: Leukemia. 2018 Nov 28;33(4):893–904. doi: 10.1038/s41375-018-0297-4

Figure 2. Multiple colour FISH showing examples of the sub-clonal nature of (A) IGH-CRLF2 (B) P2RY8-CRLF2.

Figure 2

  • Representative FISH images on the right show examples of each leukaemic sub-clone.
  • DAPI has been removed from panel B in order for the PAX5 aqua signals to be observed.
  • Leukaemic sub-clone percentages for the diagnostic samples are indicated next to each clone and only include populations above the 8% cut off.
  • Dotted clone with “?”: presumed but undetected founder clone.

(A) For patient 3789 a total of 144 abnormal nuclei at diagnosis were scored for probes to CRLF2 (red/green) and IKZF1 (gold). In 11% of nuclei both copies of IKZF1 are deleted. This clone subsequently acquires the IGH-CRLF2 translocation in a further 83% of cells.

(B) For patient 2017 a total of 211 abnormal nuclei at diagnosis were scored for probes to CRLF2 (red/green) and CDKN2A/B (gold) and PAX5 (aqua). The earliest abnormal clone detected has loss of a single copy of CDK2NA/B and PAX5 suggesting P2RY8-CRLF2 is a sub-clonal event. This clone acquired P2RY8-CRLF2 in a further 70% of nuclei.